share_log

Cantor Fitzgerald Initiates Coverage On KemPharm With Overweight Rating, Announces Price Target of $20

Cantor Fitzgerald Initiates Coverage On KemPharm With Overweight Rating, Announces Price Target of $20

康托·菲茨杰拉德以增持评级启动对KemPharm的报道,宣布目标价为20美元
Benzinga Real-time News ·  2022/11/17 06:22

Cantor Fitzgerald analyst Louis Chen initiates coverage on KemPharm (NASDAQ:KMPH) with a Overweight rating and announces Price Target of $20.

Cantor Fitzgerald分析师Louis Chen在纳斯达克(KemPharm)上以增持评级启动报道,并宣布目标价为20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发